Clinical trials
Primary Hepatocellular Carcinoma clinical trials
Below are recruiting primary hepatocellular carcinoma clinical trials, each written for real people, not researchers. We’re tracking 177 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04365751Recruiting
Microwave ablation versus surgery for liver cancer
This trial compares two ways to treat hepatocellular carcinoma (a type of liver cancer): microwave ablation and laparoscopic hepatectomy (keyhole liver surgery). It may help find which option works better for tumor control and recovery in people with limited, non-spread cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05926726Recruiting
GPC3-targeted CAR-T for advanced liver cancer
This trial tests a custom immune-cell treatment (CAR-T) that targets a marker called GPC3 in people with advanced hepatocellular carcinoma (a type of liver cancer). It’s for cases where standard treatments have not worked well, and the goal is to shrink tumors and improve outcomes.
ShanghaiAges 18–75 - NCT05954897RecruitingPhase 2
Lenvatinib plus tislelizumab with HAIC for advanced liver cancer
This Phase 2 study tests whether combining three treatments—lenvatinib, tislelizumab, and a liver-directed chemotherapy approach (HAIC)—can shrink advanced hepatocellular carcinoma. It may help people whose cancer is stage C and hasn’t been treated before.
Guangzhou, GuangdongAges 18 years+ - NCT05444478Recruiting
Microwave ablation plus lenvatinib for recurrent liver cancer
This trial tests whether combining heat treatment to kill liver tumors (microwave ablation) with the medicine lenvatinib can better control recurrent hepatocellular carcinoma (HCC). It may help shrink tumors or slow growth for people whose cancer has come back but who have limited tumor burden.
Changsha, HunanAges 18–75 - NCT06326502RecruitingPhase 1
A study of ETN101 for advanced liver cancer
This trial tests an experimental oral drug (ETN101) for adults with advanced liver cancer (hepatocellular carcinoma) that has gotten worse after standard treatments or can't be treated with standard therapy. It aims to see if the drug is safe and effective.
SeoulAges 19–65 - NCT06406634RecruitingPhase 2
Cadonilimab, Lenvatinib, and HAIC for Unresectable Liver Cancer
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
Changsha, HunanAges 18–75 - NCT07848750Recruiting
Finger-press test for liver cancer detection
This study tests a new, non-invasive finger-press test that may help detect liver cancer (hepatocellular carcinoma). It compares results from people with liver cancer, people with benign liver disease, and healthy people to see if the test can tell them apart.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07793695RecruitingPhase 2
Zinc plus immune therapy for advanced liver cancer
This study tests whether adding zinc supplements to standard targeted and immunotherapy improves outcomes for people with advanced liver cancer. Zinc may help the immune system work better against cancer cells.
Hefei, AnhuiAges 18–75 - NCT06519578Recruiting
Liver Cancer Study: Comparing Two Chemotherapy Drugs via Artery Infusion
This study compares two chemotherapy drugs (raltitrexed and 5-fluorouracil) given directly into the liver's main artery to treat liver cancer. It aims to see which drug works better and is safer for people with hepatocellular carcinoma.
ShanghaiAges 18–75 - NCT07782632Recruiting
Imaging scans to predict immunotherapy response in liver cancer
This study looks at how doctors can use imaging scans to predict how well immunotherapy will work for people with liver cancer that cannot be removed by surgery. Participants must have already received immunotherapy and have had baseline scans.
Hefei, AnhuiAges 18–75 - NCT06623474Recruiting
Fat markers in blood for liver cancer study
This study is for people having liver cancer surgery. It will look at certain fats in your blood to see if they can help doctors understand and track liver cancer better.
Guangzhou, GuangdongAges 18–80 - NCT06652243RecruitingEarly Phase 1
Cell therapy for advanced liver cancer with GPC3 protein
This trial tests a new cell therapy called SN301A for people with advanced liver cancer that has a specific protein (GPC3) on the tumor cells. The goal is to see if this treatment can help when other treatments have stopped working.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07538882Recruiting
AI-Assisted Staging and Treatment Planning for Liver Cancer
This trial uses artificial intelligence to help doctors better stage (classify the severity of) and plan treatment for hepatocellular carcinoma, a type of primary liver cancer. Researchers will collect your clinical information and imaging to see if AI can improve decision-making about your care.
Beijing, ChangpingAges 18 years+ - NCT07482059RecruitingPhase 1/Phase 2
Combination therapy for advanced liver cancer
This trial tests a combination of treatments for liver cancer that cannot be removed by surgery. It uses a special radiation therapy called Y90 along with other drugs to see if they work better together.
Chengdu, SichuanAges 18–80 - NCT06333561Recruiting
Combination therapy for infiltrative liver cancer
This trial tests a three-drug combination for a specific type of liver cancer called infiltrative hepatocellular carcinoma. It combines a liver-directed chemotherapy infusion (HAIC) with two oral and intravenous drugs (lenvatinib and a PD-1 inhibitor) to see if it works better than lenvatinib alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT07391839RecruitingPhase 1
MDN-001 injection for liver cancer that can't be surgically removed
This trial tests an injection called MDN-001 for people with liver cancer (hepatocellular carcinoma) that cannot be removed by surgery or other local treatments. The goal is to see if it is safe and effective for patients whose cancer has not spread outside the liver.
Hefei, AnhuiAges 18–80 - NCT05417932RecruitingPhase 1/Phase 2
Cell therapy for hepatitis B–related liver cancer
This Phase 1/2 study tests a lab-made cell treatment (SCG101) for people with hepatitis B–related liver cancer who have already had standard treatments. It aims to shrink tumors and improve outcomes in carefully selected patients.
New York, New YorkAges 18–70 - NCT07317414RecruitingPhase 2
Beta-alanine for advanced liver cancer
This trial tests whether beta-alanine, a natural supplement, can help people with advanced liver cancer that cannot be removed by surgery. It aims to see if the treatment can slow tumor growth and improve outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT07324824RecruitingPhase 2
Sintilimab plus bevacizumab before surgery for liver cancer
This trial tests two drugs, sintilimab and bevacizumab, given before surgery to treat liver cancer that can be removed. It's for people with a certain stage of liver cancer who haven't had other treatments.
Guangzhou, GuangdongAges 18 years+ - NCT06864221Recruiting
How fat molecules in blood affect liver cancer radiotherapy
This study looks at whether certain fats in your blood can help predict how well radiotherapy works for liver cancer. If you are getting radiation for liver cancer, your blood samples may help doctors learn more about your treatment response.
Guangzhou, GuangdongAges 18–80 - NCT07291141Recruiting
MRI vs. Ultrasound for Liver Cancer Detection in Cirrhosis
This study compares MRI and ultrasound to see which is better at finding liver cancer early in people with liver cirrhosis. It also looks at body composition and other factors that could lead to worsening liver function.
Linköping, Select A State Or ProvinceAges 18 years+ - NCT07285044RecruitingPhase 2
Home cancer treatment program for Florida panhandle residents
This study tests whether people with certain cancers can safely receive their regular intravenous treatments at home instead of coming to the clinic. It aims to make treatment more convenient and improve satisfaction, especially for those living in the Florida Panhandle.
Jacksonville, FloridaAges 18 years+ - NCT05713994Recruiting
Liver cancer treatments together for unresectable liver tumors
This trial tests a combined treatment plan—chemo delivered to the liver, targeted therapy, anti-VEGF therapy, and immunotherapy—to control unresectable hepatocellular carcinoma (HCC). It may help shrink tumors or slow progression when surgery isn’t possible.
Quanzhou, FujianAges 18 years+ - NCT06641713Recruiting
Comparing two liver cancer treatments for large tumors
This trial compares two treatments for people with large liver tumors. One is a liver artery chemotherapy infusion and the other is a chemo-embolization procedure. The study will see which approach works better.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new Primary Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for primary hepatocellular carcinoma?
- Yes. Clin2 currently lists 177 recruiting primary hepatocellular carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a primary hepatocellular carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a primary hepatocellular carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.